Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23370440 | 0.88 | CYP1A2 (0.37) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23370304 | 0.88 | CYP1A2 (0.33) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29814445 | 0.88 | CYP1A2 (0.33) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24853568 | 0.86 | CYP1A2 (0.32) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29814635 | 0.86 | ESR1 (0.33) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23370308 | 0.86 | ESR1 (0.33) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23370330 | 0.86 | ESR1 (0.33) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24854239 | 0.85 | CYP1A2 (0.33) | CYP1A2CYP3A4CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL24854536 | 0.84 | BUB1 (0.35) | ADORA2ACYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23361237 | 0.83 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2D6CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002357-A1 | 7-PYRIMIDINE-2-YL-OXY-INDAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-4058444-A1 | 7-PYRIMIDINE-2-YL-OXY-INDAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | Syngenta Crop Protection AG (CH) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002357-A1 | 7-PYRIMIDINE-2-YL-OXY-INDAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | AZI2, PDXK, DPYD | ADORA2A 1751/4885CYP1A2 30/4885CYP3A4 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.